Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab Autoinjector Usability Study in Severe Eosinophilic Asthma
NCT03099096Phase 3Completed
- Sponsor
- GSK
- Start
- May 2017
- Primary completion
- Nov 2017
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of mepolizumab in eosinophilic asthma (EA), sponsored by GSK. Started May 2017; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT03099096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099096.